Work

Additional file 2: Table S2. of The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer

Year: 2017

Type: article

Abstract: Combined SW IV-134 and gemcitabine therapy does not induce changes in serum chemistries in tumor-bearing mice. Biochemical analysis of immunocompromised nude mice treated daily with SW IV-134 and weekly gemcitabine for 3 weeks compared to vehicle (control). The differences in laboratory values between the two groups were not statistically significant. (PDF 16 kb)

Source: Figshare

DOI: 10.6084/m9.figshare.4559602

Authors: Hashim, Yassar, Vangveravong, Suwanna, Sankpal, Narendra, Binder, Pratibha, Liu, Jingxia, Goedegebuure, S., Mach, Robert, Spitzer, Dirk, Hawkins, William

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7136091647

FWCI:

Cites:

Cited by:

Related to: 10